Achilles Therapeutics (Achilles Therapeutics) Interest Expense : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Achilles Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Achilles Therapeutics's interest expense for the three months ended in Mar. 2024 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Achilles Therapeutics's Operating Income for the three months ended in Mar. 2024 was $ -14.30 Mil. Achilles Therapeutics's Interest Expense for the three months ended in Mar. 2024 was $ 0.00 Mil. GuruFocus does not calculate Achilles Therapeutics's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Achilles Therapeutics Interest Expense Historical Data

The historical data trend for Achilles Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achilles Therapeutics Interest Expense Chart

Achilles Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Achilles Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial													-	-	-	-	-

Achilles Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Achilles Therapeutics (NAS:ACHL) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Achilles Therapeutics's Interest Expense for the three months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-14.30 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $0.58 Mil.

Achilles Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

GuruFocus does not calculate Achilles Therapeutics's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Achilles Therapeutics PLC has enough cash to cover all of its debt. Its financial situation is stable.

Achilles Therapeutics (Achilles Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achilles Therapeutics PLC (NAS:ACHL) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

698:Germany

Address

245 Hammersmith Road, London, GBR, W6 8PW

Website

https://www.achillestx.com

Achilles Therapeutics PLC is a biopharmaceutical company. It is developing novel cancer immunotherapies targeting clonal neoantigens. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.